KRAS Mutant Cancer Therapy
Unlock KRAS-targeted therapy insights at Appleglc.com — adagrasib, sotorasib, and emerging G12C inhibitor combinations for lung, colorectal, and pancreatic KRAS-mutant cancer patients.
Lumakras
Sotorasib
Krazati
Adagrasib
Adagrasib
Adagrasib
Sotorasib
Sotorasib
Keytruda
Pembrolizumab
Opdivo
Nivolumab
Avastin
Bevacizumab
Mvasi
Bevacizumab-awwb
Zirabev
Bevacizumab-bvzr
Cyramza
Ramucirumab
Erbitux
Cetuximab
Vectibix
Panitumumab
Taxol
Paclitaxel
Taxotere
Docetaxel
Abraxane
Paclitaxel Protein-Bound Particles
Gemzar
Gemcitabine Hydrochloride
Eloxatin
Oxaliplatin
Camptosar
Irinotecan Hydrochloride
Adrucil
Fluorouracil Injection
Wellcovorin
Leucovorin Calcium
Xeloda
Capecitabine
Lonsurf
Trifluridine and Tipiracil Hydrochloride
Stivarga
Regorafenib
Tecentriq
Atezolizumab
Imfinzi
Durvalumab
Bavencio
Avelumab
Libtayo
Cemiplimab-rwlc
Opdualag
Nivolumab and Relatlimab-rmbw
Nivolumab SC
Nivolumab and Hyaluronidase-nvhy
Pembrolizumab IV
Pembrolizumab
Rybrevant
Amivantamab-vmjw
Tepmetko
Tepotinib
Tabrecta
Capmatinib
Retevmo
Selpercatinib
Rozlytrek
Entrectinib
Vitrakvi
Larotrectinib Sulfate
Gavreto
Pralsetinib
Augtyro
Repotrectinib
Paraplatin
Carboplatin
Platinol
Cisplatin